News Image

Hoth Therapeutics Secures Key European Regulatory Milestone with EMA Submission for Phase II Trial of HT-001 in Cancer Patients Suffering from EGFRi-Induced Skin Toxicities

Provided By PR Newswire

Last update: Sep 10, 2025

NEW YORK, Sept. 10, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical innovator, today announced it has submitted its Clinical Trial Application (CTA) to the European Medicines Agency (EMA) to expand its ongoing Phase II trial of HT-001, a novel topical therapeutic for skin toxicities associated with Epidermal Growth Factor Receptor inhibitors (EGFRi).

Read more at prnewswire.com

HOTH THERAPEUTICS INC

NASDAQ:HOTH (10/24/2025, 8:00:01 PM)

After market: 1.3601 -0.01 (-0.72%)

1.37

+0.01 (+0.74%)



Find more stocks in the Stock Screener

Follow ChartMill for more